{"log_id": 7143750969469705697, "direction": 0, "words_result_num": 43, "words_result": [{"probability": {"variance": 9e-06, "average": 0.998402, "min": 0.987654}, "location": {"width": 348, "top": 154, "height": 34, "left": 157}, "words": "管型尿、尿白细胞阳性、尿蛋白阳性"}, {"probability": {"variance": 0, "average": 0.999422, "min": 0.998969}, "location": {"width": 110, "top": 196, "height": 25, "left": 203}, "words": "心血管风险"}, {"probability": {"variance": 0.000207, "average": 0.994333, "min": 0.913406}, "location": {"width": 792, "top": 226, "height": 35, "left": 201}, "words": "在随机对照及长期扩展性研究中,心血管事件和死亡是APTC(Anti- Platelet Trialist"}, {"probability": {"variance": 0, "average": 0.968293, "min": 0.968293}, "location": {"width": 54, "top": 278, "height": 19, "left": 160}, "words": " Collab"}, {"probability": {"variance": 8e-06, "average": 0.998144, "min": 0.986323}, "location": {"width": 697, "top": 262, "height": 36, "left": 310}, "words": "预先确定的终点(包括心血管死亡、非致死性心肌梗死、非致死性卒中)之"}, {"probability": {"variance": 0.000537, "average": 0.99096, "min": 0.890841}, "location": {"width": 807, "top": 300, "height": 38, "left": 201}, "words": "在随机对照的Ⅲ期试验中,每100例患者一年APTC事件的发生率分别是:安慰剂组"}, {"probability": {"variance": 0.012449, "average": 0.946449, "min": 0.599052}, "location": {"width": 135, "top": 352, "height": 20, "left": 190}, "words": "95%CI0.00-6"}, {"probability": {"variance": 0.023132, "average": 0.919178, "min": 0.3667}, "location": {"width": 613, "top": 338, "height": 37, "left": 391}, "words": "非布司他40mg组0(95%C0.00-1.08)、非布司他80mg组1.09"}, {"probability": {"variance": 0.021602, "average": 0.916397, "min": 0.574743}, "location": {"width": 152, "top": 388, "height": 21, "left": 182}, "words": "95%C10.442.24"}, {"probability": {"variance": 0.005436, "average": 0.974111, "min": 0.631314}, "location": {"width": 315, "top": 380, "height": 31, "left": 382}, "words": "别嘌醇组0.60(95%CI0.16-1.53)"}, {"probability": {"variance": 0.000621, "average": 0.988914, "min": 0.864631}, "location": {"width": 802, "top": 412, "height": 38, "left": 202}, "words": "在长期扩展性研究中,APTC事件的发生率分别是:非布司他80mg组0.97(95%C"}, {"probability": {"variance": 0.004708, "average": 0.968348, "min": 0.625591}, "location": {"width": 452, "top": 458, "height": 26, "left": 160}, "words": "057-1.56,和别嘌醇组0.58(95%C10.02-3.24"}, {"probability": {"variance": 0.000472, "average": 0.990422, "min": 0.894603}, "location": {"width": 809, "top": 485, "height": 39, "left": 203}, "words": "总之,相比于别嘌醇组,非布司他治疗组具有较高的APTC事件发生率,但与非布司"}, {"probability": {"variance": 0.000117, "average": 0.995037, "min": 0.949286}, "location": {"width": 666, "top": 524, "height": 37, "left": 160}, "words": "他的因果关系还未确定。服药时应监测心肌梗死和脑卒中的症状和体征"}, {"probability": {"variance": 0.03778, "average": 0.899995, "min": 0.415081}, "location": {"width": 187, "top": 569, "height": 25, "left": 203}, "words": "2.产上市后经验"}, {"probability": {"variance": 0.009544, "average": 0.973535, "min": 0.555105}, "location": {"width": 806, "top": 596, "height": 37, "left": 203}, "words": "对非布司他上市后使用中的不良反应进行了甄别。由于这些不良反应是从未知数量的患"}, {"probability": {"variance": 0.002504, "average": 0.980335, "min": 0.71976}, "location": {"width": 782, "top": 634, "height": 41, "left": 163}, "words": "者中自发报告的,因此不可能准确评估其发生频率或判定其与药物的因果关系药"}, {"probability": {"variance": 0.000921, "average": 0.990568, "min": 0.819759}, "location": {"width": 788, "top": 666, "height": 42, "left": 202}, "words": "肝胆异常:肝功能衰竭(有些是致命的)黄疸、肝功能检查结果严重异常、肝脏疾病"}, {"probability": {"variance": 0.001727, "average": 0.984993, "min": 0.867454}, "location": {"width": 198, "top": 711, "height": 32, "left": 202}, "words": "免疫系统:过敏反应"}, {"probability": {"variance": 0.000683, "average": 0.990508, "min": 0.892059}, "location": {"width": 349, "top": 746, "height": 32, "left": 202}, "words": "肌肉骨骼和结缔组织:横纹肌溶解症"}, {"probability": {"variance": 4.3e-05, "average": 0.997243, "min": 0.970658}, "location": {"width": 393, "top": 781, "height": 34, "left": 202}, "words": "精神异常:包括攻击性倾向的精神病行为"}, {"probability": {"variance": 0.000539, "average": 0.986506, "min": 0.922048}, "location": {"width": 283, "top": 821, "height": 27, "left": 203}, "words": "泌尿系统:肾小管间质性肾炎"}, {"probability": {"variance": 0.000168, "average": 0.992659, "min": 0.945912}, "location": {"width": 319, "top": 856, "height": 31, "left": 205}, "words": "皮肤和皮下组织:全身性皮疹,St"}, {"probability": {"variance": 0.00072, "average": 0.982922, "min": 0.920088}, "location": {"width": 285, "top": 853, "height": 27, "left": 582}, "words": " ohnson综合征,皮肤过敏反应"}, {"probability": {"variance": 6.9e-05, "average": 0.994133, "min": 0.979793}, "location": {"width": 80, "top": 898, "height": 26, "left": 166}, "words": "【禁忌】"}, {"probability": {"variance": 0.010406, "average": 0.958679, "min": 0.621728}, "location": {"width": 474, "top": 928, "height": 34, "left": 205}, "words": "本品禁用于正在接受硫唑驃呤、巯嘌呤治疗的患者"}, {"probability": {"variance": 8e-06, "average": 0.998334, "min": 0.991969}, "location": {"width": 119, "top": 972, "height": 26, "left": 168}, "words": "【注意事项】"}, {"probability": {"variance": 0, "average": 0.999589, "min": 0.999048}, "location": {"width": 89, "top": 1009, "height": 26, "left": 204}, "words": "痛风发作"}, {"probability": {"variance": 0.000104, "average": 0.995972, "min": 0.945679}, "location": {"width": 805, "top": 1035, "height": 39, "left": 205}, "words": "在服用非布司他的初期,经常出现痛风发作频率增加。这是因为血尿酸浓度降低,导致"}, {"probability": {"variance": 0.001978, "average": 0.989327, "min": 0.725044}, "location": {"width": 850, "top": 1072, "height": 37, "left": 160}, "words": "组织中沉积的尿酸盐动员。为预防治疗初期的痛风发作,建议同时服用非甾体类抗炎药或秋"}, {"probability": {"variance": 0.000757, "average": 0.979666, "min": 0.940754}, "location": {"width": 67, "top": 1120, "height": 25, "left": 163}, "words": "水仙碱"}, {"probability": {"variance": 0.001645, "average": 0.983145, "min": 0.825128}, "location": {"width": 782, "top": 1145, "height": 37, "left": 205}, "words": "在非布司他治疗期间,如果痛风发作,无需中止非布司他治疗。应根据患者的具体情况"}, {"probability": {"variance": 2e-06, "average": 0.999183, "min": 0.995828}, "location": {"width": 194, "top": 1192, "height": 26, "left": 163}, "words": "对痛风进行相应治疗"}, {"probability": {"variance": 1e-06, "average": 0.998401, "min": 0.996438}, "location": {"width": 109, "top": 1227, "height": 25, "left": 206}, "words": "心血管事件"}, {"probability": {"variance": 0.000392, "average": 0.991538, "min": 0.902222}, "location": {"width": 805, "top": 1254, "height": 38, "left": 205}, "words": "在随机对照研究中,相比使用别嘌醇,使用非布司他治疗的患者发生心血管血栓事件(包"}, {"probability": {"variance": 0.010666, "average": 0.965859, "min": 0.414157}, "location": {"width": 845, "top": 1291, "height": 37, "left": 162}, "words": "括心血管死亡、非致死性心肌梗死、非致死性脑卒中)的概率较高,其中非布司他为0.7410"}, {"probability": {"variance": 0.015937, "average": 0.933532, "min": 0.397352}, "location": {"width": 848, "top": 1331, "height": 33, "left": 162}, "words": "例患者一年(95%C:0.36-1.37),别嘌醇为0.60/100例患者一年(95%C1:0.16-.3)。尚"}, {"probability": {"variance": 0.006055, "average": 0.981004, "min": 0.59599}, "location": {"width": 852, "top": 1366, "height": 37, "left": 162}, "words": "未确定非布司他与心血管血栓事件的因果关系。用药时注意监测心肌梗死和脑卒中的症状及"}, {"probability": {"variance": 2.9e-05, "average": 0.994294, "min": 0.988881}, "location": {"width": 45, "top": 1413, "height": 24, "left": 162}, "words": "体征"}, {"probability": {"variance": 4e-06, "average": 0.998317, "min": 0.994387}, "location": {"width": 113, "top": 1448, "height": 26, "left": 205}, "words": "肝脏的影响"}, {"probability": {"variance": 0.00231, "average": 0.98412, "min": 0.737247}, "location": {"width": 805, "top": 1476, "height": 37, "left": 207}, "words": "已有患者服用非布司他后出现致死性和非致死性肝脏衰竭的上市后报告,尽管这些报告"}, {"probability": {"variance": 0.005862, "average": 0.98472, "min": 0.508052}, "location": {"width": 849, "top": 1514, "height": 37, "left": 163}, "words": "内确定它们之间因果关系的信息尚不充分。在随机对照研究中,观察到转氨酶可升高至正常"}, {"probability": {"variance": 0.00225, "average": 0.979703, "min": 0.714673}, "location": {"width": 827, "top": 1551, "height": 35, "left": 163}, "words": "范围值上限(ULN)的3倍以上(非布司他、别嘌醇治疗组的发生率分别为AST:2%,2%"}], "language": 3}